First Patient Receives Gene-Edited Islet Transplant Without Immunosuppression

For the first time, a patient with type 1 diabetes has received a transplant of insulin-producing islet cells that were genetically engineered to avoid immune rejection—without needing immunosuppressive medications afterward. The breakthrough case, published in the New England Journal of Medicine, offers a potential pathway to cell transplantation that could reduce the burden of lifelong drug therapy.

The transplanted cells were modified using CRISPR-associated protein 12b (Cas12b) gene editing and lentiviral transduction techniques. These genetic modifications were designed to make the donor cells "hypoimmune"—essentially invisible to the recipient's immune system so they would not be attacked and destroyed.

The patient received no glucocorticoids, anti-inflammatory drugs, or immunosuppressive medications after the transplant. At the 12-week mark, testing showed he had not mounted an immune response against the gene-edited cells.

Blood sugar control improved significantly during this period. His HbA1c—a measure of average blood glucose over time—dropped approximately 42%. Measurements of C-peptide, a marker of insulin production, showed the transplanted cells were making insulin in a way that responded appropriately to changes in blood glucose.

This case demonstrates that the concept of immune-evasive, gene-edited islet cell transplants is feasible in humans. It opens a potential new avenue for treating type 1 diabetes without the complications of long-term immunosuppression.

However, this is a first-in-human report based on one patient followed for 12 weeks. Researchers emphasize that longer follow-up will be needed to understand whether the approach is safe, whether the cells continue to work over months and years, and whether the immune protection holds up over time. Many questions remain before this approach could become widely available.

Origin: medpagetoday.com (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.